PacBio engineers $800M buyout of sequencing rival Omniome as analysts fret over FTC action
As Illumina runs into another regulatory roadblock to expansion, one of its almost-subsidiaries is charging ahead with a new buyout.
Pacific Biosciences, often referred …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
